Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

BACKGROUND: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk–benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported symptoms, functioning, and health-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M.-J., Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S., Demetri, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100628/
https://www.ncbi.nlm.nih.gov/pubmed/33930659
http://dx.doi.org/10.1016/j.esmoop.2021.100113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100628/
https://www.ncbi.nlm.nih.gov/pubmed/33930659
http://dx.doi.org/10.1016/j.esmoop.2021.100113

Ejemplares similares